Evidence map›Paper›PMID 33121334›Full record

ArticlemAbs

Removal of variable domain

Gwo-Yu Chuang, Mangaiarkarasi Asokan, Vera B Ivleva, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Rajoshi Chaudhuri, Hui Geng, Bob C Lin, Mark K Louder and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Gwo-Yu ChuangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Mangaiarkarasi AsokanVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Vera B IvlevaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Amarendra PeguVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.ORCID 0000-0003-3564-6453
Eun Sung YangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Baoshan ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Rajoshi ChaudhuriVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Hui GengVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Bob C LinVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Krisha McKeeVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Hairong WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Lisa A KueltzoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Q Paula LeiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MA, USA.ORCID 0000-0003-3560-232X
National Institutes of Health · US

Funding

Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
Intramural NIH HHS ZIA AI005022
6 · The paper itself

Abstract

Broadly neutralizing antibodies are showing promise in the treatment and prevention of HIV-1, with several now being evaluated clinically. Some lead clinical candidates, including antibodies CAP256-VRC26.25, N6, PGT121, and VRC07-523, have one or more

Indexed as

HIV-1AnimalsBroadly Neutralizing AntibodiesGlycosylationHIV AntibodiesHIV InfectionsHumansImmunoglobulin Variable RegionMicePolysaccharidesBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin Variable RegionPolysaccharidesAntibody engineeringbroadly neutralizing antibodiesheterogeneityHIV-1n-linked glycosylationpolyreactivitystructure-based design

Identifiers

PMID33121334
PMCPMC7643989
OpenAlexW3095967598

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.